SS
VNDA icon

SBI Securities’s Vanda Pharmaceuticals VNDA Stock Holding History

SBI Securities’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61 Buy
10
+3
+43% +$20 ﹤0.01% 3627
2026
Q1 		$48 Sell
7
-6
-46% -$46 ﹤0.01% 3583
2025
Q4 		$115 Sell
13
-28
-68% -$154 ﹤0.01% 3366
2025
Q3 		$205 Buy
41
+1
+3% +$5 ﹤0.01% 3312
2025
Q2 		$189 Sell
40
-50
-56% -$219 ﹤0.01% 3333
2025
Q1 		$413 Buy
90
+50
+125% +$233 ﹤0.01% 2939
2024
Q4 		$192 Buy
+40
New +$192 ﹤0.01% 3258

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's VNDA Position: Q2 2026 in Review

SBI Securities increased its Vanda Pharmaceuticals (VNDA) stake by 43% in Q2 2026, buying an estimated $20 and bringing the position to 10 shares worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #3627.

SBI Securities first reported a position in VNDA in Q4 2024 and has held it in 7 quarters since. The position peaked at $413 in Q1 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • SBI Securities held 10 shares of Vanda Pharmaceuticals worth $61 as of Q2 2026.
  • SBI Securities bought 3 Vanda Pharmaceuticals shares in Q2 2026, an estimated $20.
  • Vanda Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3627 holding.
  • SBI Securities first reported a position in Vanda Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Vanda Pharmaceuticals position peaked at $413 in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.